Biden Administration Devotes Over $3.2B For Development Of Oral Antiviral Therapies For COVID-19: CNBC
Officials on Thursday announced that the Biden Administration plans to invest more than $3.2 billion in developing antiviral medicines to…
Merck Announces Supply Agreement With U.S. Government For Molnupiravir Investigational Oral Antiviral Candidate For Treatment Of Mild To Moderate COVID-19
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for Molnupiravir (MK-4482).
Fusion Pharma’s Stock Moves Higher As Radiopharmaceutical Candidate Shows Early Promising Action In Solid Tumor Study
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) has announced preliminary Phase 1 data from the single-dose portion of the study evaluating FPI-1434 in patients…
‘Fast Money Halftime Report’ Picks For June 11
On CNBC's "Fast Money Halftime Report," Shannon Saccocia said it might be a good time to enter Merck & Co., Inc. (NYSE: MRK).
The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 3)
AstraZeneca, Merck Lynparza Earns Win in Early Breast Cancer, Showing Potential in Post-Surgery Setting
AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) have announced the first presentation of data from the Phase 3 OlympiA trial evaluating…
Merck’s Keytruda Shows Clinical Benefit in Post-Surgery Kidney Cancer Setting
Merck & Co (NYSE:MRK) announced first-time results from the pivotal Phase 3 KEYNOTE-564 trial evaluating Keytruda for the potential adjuvant treatment…
AstraZeneca, Merck Report Results From OlympiA Phase 3 Trial Of LYNPARZA For Patients With Germline Breast Cancer Gene-Mutated High-Risk Early Breast Cancer Showed Statistical Significance, Clinically Meaningful Improvement In Survival
First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
WILMINGTON, Del.--(BUSINESS WIRE)--
AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced
Merck Says Co’s KEYTRUDA (pembrolizumab) Given After Surgery Reduced Risk Of Disease Recurrence Or Death By 32% Versus Placebo As Adjuvant Therapy In Patients With Renal Cell Carcinoma (RCC)
Merck's KEYTRUDA® (pembrolizumab) Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal Cell Carcinoma (RCC)
KEYNOTE-564 is the
Merck Completes Women’s Health Organon Spinoff
In a move to free up a cash windfall and streamline the business, Merck & Co Inc (NYSE: MRK) had long planned to slice away its women’s health business into a standalone spinoff.